Impact of SAfinamide on Depressive Symptoms in Parkinson’s Disease Patients (SADness-PD Study): A Multicenter Retrospective Study

Background: We aimed to assess the effects of safinamide on depression, motor symptoms, and the serotonin syndrome related to its co-administration with antidepressants in patients with Parkinson’s disease (PD). Methods: We retrospectively analyzed the data of patients at 1 and 3 months of follow-up compared to baseline. Results: n = 82 (safinamide 50 mg = 22, 100 mg = 60, with antidepressants = 44). First, we found improvement in depression (Hamilton Depression Rating Scale: −6 ± 5.10 at 1 month and −7.27 ± 5.10 at 3 months, p < 0.0001; Patient Global Impression of Improvement Scale: 60.3% and 69.5% of patients at 1 and 3 months reported some improvement). Second, safinamide improved the daily life activities and motor symptoms/motor complications (Unified Parkinson’s Disease Rating Scale (UPDRS-II): −2.51 ± 6.30 and −2.47 ± 6.11 at 1 and 3 months, p < 0.0001; III: −3.58 ± 8.68 and −4.03 ± 8.95 at 1 and 3 months, p < 0.0001; IV: −0.61 ± 2.61 and −0.8 ± 2.53 at 1 and 3 months, p < 0.0001). Third, 7.31% and 8.53% of patients developed non-severe adverse events related to safinamide at 1 and 3 months. Serotonin syndrome was not observed in the patients treated with antidepressants; some isolated serotonin syndrome symptoms were reported. Conclusions: Safinamide could be useful for treating depression in PD; it was effective for motor symptoms and motor complications and safe even when co-administered with antidepressants. View Full-Text

Keywords: Parkinson’s disease; depression; serotonin syndrome; antidepressants; safinamide; motor symptoms

▼ Show Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share and Cite

MDPI and ACS Style

Peña, E.; Borrué, C.; Mata, M.; Martínez-Castrillo, J.C.; Alonso-Canovas, A.; Chico, J.L.; López-Manzanares, L.; Llanero, M.; Herreros-Rodríguez, J.; Esquivel, A.; Maycas-Cepeda, T.; Ruíz-Huete, C. Impact of SAfinamide on Depressive Symptoms in Parkinson’s Disease Patients (SADness-PD Study): A Multicenter Retrospective Study. Brain Sci. 2021, 11, 232. https://doi.org/10.3390/brainsci11020232

AMA Style

Peña E, Borrué C, Mata M, Martínez-Castrillo JC, Alonso-Canovas A, Chico JL, López-Manzanares L, Llanero M, Herreros-Rodríguez J, Esquivel A, Maycas-Cepeda T, Ruíz-Huete C. Impact of SAfinamide on Depressive Symptoms in Parkinson’s Disease Patients (SADness-PD Study): A Multicenter Retrospective Study. Brain Sciences. 2021; 11(2):232. https://doi.org/10.3390/brainsci11020232

Chicago/Turabian Style

Peña, Esteban, Carmen Borrué, Marina Mata, Juan Carlos Martínez-Castrillo, Araceli Alonso-Canovas, Juan Luis Chico, Lydia López-Manzanares, Marcos Llanero, Jaime Herreros-Rodríguez, Alberto Esquivel, Teresa Maycas-Cepeda, and Cristina Ruíz-Huete. 2021. "Impact of SAfinamide on Depressive Symptoms in Parkinson’s Disease Patients (SADness-PD Study): A Multicenter Retrospective Study" Brain Sciences 11, no. 2: 232. https://doi.org/10.3390/brainsci11020232

Find Other Styles

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Abstract views Pdf views Html views

Article Menu

Impact of SAfinamide on Depressive Symptoms in Parkinson’s Disease Patients (SADness-PD Study): A Multicenter Retrospective Study

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Article Access Map by Country/Region

Further Information

Guidelines

MDPI Initiatives

Follow MDPI